Follow
Aaron Mitchell
Title
Cited by
Cited by
Year
In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-α
MK Connolly, AS Bedrosian, JMS Clair, AP Mitchell, J Ibrahim, A Stroud, ...
The Journal of clinical investigation 119 (11), 3213-3225, 2009
3442009
Function and dynamics of PKD2 in Chlamydomonas reinhardtii flagella
K Huang, DR Diener, A Mitchell, GJ Pazour, GB Witman, JL Rosenbaum
The Journal of cell biology 179 (3), 501-514, 2007
2152007
Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review
AP Mitchell, NU Trivedi, RL Gennarelli, S Chimonas, SM Tabatabai, ...
Annals of internal medicine 174 (3), 353-361, 2021
1762021
Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver
J Ibrahim, AH Nguyen, A Rehman, A Ochi, M Jamal, CS Graffeo, ...
Gastroenterology 143 (4), 1061-1072, 2012
1702012
Financial relationships with industry among National Comprehensive Cancer Network guideline authors
AP Mitchell, EM Basch, SB Dusetzina
JAMA oncology 2 (12), 1628-1631, 2016
1132016
Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice
AP Mitchell, MR Harrison, MS Walker, DJ George, AP Abernethy, ...
Journal of oncology practice 11 (6), 491-497, 2015
792015
Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States
AP Mitchell, RJ Simpson
BMC research notes 5, 1-6, 2012
632012
Pharmaceutical industry payments and oncologists’ selection of targeted cancer therapies in medicare beneficiaries
AP Mitchell, AN Winn, SB Dusetzina
JAMA Internal Medicine 178 (6), 854-856, 2018
522018
Evaluating the strength of the association between industry payments and prescribing practices in oncology
AP Mitchell, AN Winn, JL Lund, SB Dusetzina
The Oncologist 24 (5), 632-639, 2019
382019
Association between reimbursement incentives and physician practice in oncology: a systematic review
AP Mitchell, JS Rotter, E Patel, D Richardson, SB Wheeler, E Basch, ...
JAMA oncology 5 (6), 893-899, 2019
362019
Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform
T Torgerson, C Wayant, L Cosgrove, EA Akl, J Checketts, R Dal Re, J Gill, ...
BMJ evidence-based medicine 27 (1), 46-54, 2022
252022
Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial
EF Gillespie, JC Yang, NJ Mathis, CB Marine, C White, Z Zhang, ...
Journal of Clinical Oncology 42 (1), 38-46, 2024
232024
Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics
A Mitchell, B Muluneh, R Patel, E Basch
Journal of Oncology Pharmacy Practice 24 (6), 424-432, 2018
232018
Deferred systemic therapy in patients with metastatic renal cell carcinoma
AP Mitchell, BR Hirsch, MR Harrison, AP Abernethy, DJ George
Clinical Genitourinary Cancer 13 (3), e159-e166, 2015
182015
Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis
AP Mitchell, BR Hirsch, AP Abernethy
Trials 15, 1-5, 2014
182014
Clinical trial subjects compared to" real world" patients: Generalizability of renal cell carcinoma trials.
AP Mitchell, MR Harrison, DJ George, AP Abernethy, MS Walker, ...
Journal of Clinical Oncology 32 (15_suppl), 6510-6510, 2014
162014
Cost savings and increased access with ultra-low-dose immunotherapy
AP Mitchell, DA Goldstein
Journal of Clinical Oncology 41 (2), 170, 2023
152023
Isolation of intraflagellar transport trains
C Mencarelli, A Mitchell, R Leoncini, J Rosenbaum, P Lupetti
Cytoskeleton 70 (8), 439-452, 2013
152013
Real-world use of bone-modifying agents in metastatic castration-sensitive prostate cancer
AP Mitchell, A Mishra Meza, KS Panageas, A Lipitz-Snyderman, PB Bach, ...
JNCI: Journal of the National Cancer Institute 114 (3), 419-426, 2022
142022
Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
AP Mitchell, SB Dusetzina, AM Meza, NU Trivedi, PB Bach, AN Winn
bmj 383, 2023
132023
The system can't perform the operation now. Try again later.
Articles 1–20